Neogenomics, Inc.
NEO
$6.45
-$0.155-2.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.23% | 7.55% | 10.57% | 10.44% | 11.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.23% | 7.55% | 10.57% | 10.44% | 11.97% |
| Cost of Revenue | 13.55% | 4.43% | 7.71% | 3.68% | 5.72% |
| Gross Profit | 6.02% | 11.88% | 14.31% | 20.17% | 21.04% |
| SG&A Expenses | 12.73% | 5.66% | 9.75% | 2.75% | 7.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.21% | 6.21% | 8.79% | 4.53% | 6.42% |
| Operating Income | -37.21% | 1.22% | 7.35% | 36.23% | 23.95% |
| Income Before Tax | -140.92% | 7.31% | -5.51% | 16.79% | 28.61% |
| Income Tax Expenses | -93.07% | 142.90% | 16.25% | 94.89% | 83.76% |
| Earnings from Continuing Operations | -141.88% | 4.21% | -6.97% | 4.41% | 23.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -141.88% | 4.21% | -6.97% | 4.41% | 23.38% |
| EBIT | -37.21% | 1.22% | 7.35% | 36.23% | 23.95% |
| EBITDA | -368.25% | -1.97% | 90.44% | 199.31% | 73.25% |
| EPS Basic | -138.92% | 5.17% | -5.89% | 5.36% | 24.01% |
| Normalized Basic EPS | -48.03% | -0.48% | 2.62% | 45.06% | 26.47% |
| EPS Diluted | -134.93% | 5.17% | -5.89% | 6.67% | 22.72% |
| Normalized Diluted EPS | -48.03% | -0.48% | 2.62% | 45.06% | 26.47% |
| Average Basic Shares Outstanding | 1.22% | 1.00% | 0.98% | 1.01% | 0.84% |
| Average Diluted Shares Outstanding | 1.22% | 1.00% | 0.98% | 1.01% | 0.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |